Journal
ANALYST
Volume 142, Issue 9, Pages 1569-1580Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c7an00278e
Keywords
-
Categories
Funding
- National Institutes of Health, Fogarty International Center [D43 TW009348]
- Bill and Melinda Gates Foundation: Magnetically-enabled Biomarker and Extraction Device, mBEADS [OPP1123092]
- Bill and Melinda Gates Foundation [OPP1123092] Funding Source: Bill and Melinda Gates Foundation
Ask authors/readers for more resources
Diagnosis of asymptomatic malaria poses a great challenge to global disease elimination efforts. Healthcare infrastructure in rural settings cannot support existing state-of-the-art tools necessary to diagnose asymptomatic malaria infections. Instead, lateral flow immunoassays (LFAs) are widely used as a diagnostic tool in malaria endemic areas. While LFAs are simple and easy to use, they are unable to detect low levels of parasite infection. We have developed a field deployable Magnetically-enabled Biomarker Extraction And Delivery System (mBEADS) that significantly improves limits of detection for several commercially available LFAs. Integration of mBEADS with leading commercial Plasmodium falciparum malaria LFAs improves detection limits to encompass an estimated 95% of the disease reservoir. This user-centered mBEADS platform makes significant improvements to a previously cumbersome malaria biomarker enrichment strategy by improving reagent stability, decreasing the processing time 10-fold, and reducing the assay cost 10-fold. The resulting mBEADS process adds just three minutes and less than $0.25 to the total cost of a single LFA, thus balancing sensitivity and practicality to align with the World Health Organization's ASSURED criteria for point-of-care (POC) testing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available